Business

Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023

WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. (" Medicure " or the " Company ") (TSX...

articleMedicure Inc.July 24, 20233/company/medicure-inc/news/medicure-to-present-financial-results-on-july-31-2023-call-at-830-am-et-for-quarter-ended-june-30-2023
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023

About this update from Medicure Inc.

[{"type":"text","content":"Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time. The Q2 Financials will be filed after closing July 28th, 2023.Conference Call Info:Topic: Medicure's Q2 2023 ResultsCall date: Monday, July 31, 2023Time: 7:30 AM Central Time (8:30 AM Eastern Time)Toll Free: 1 (888) 506-0062International: 1 (973) 528-0011Participant Access Code: 599508Webcast: This conference call will be webcast live over the internet at the following link: https://www.webcaster4.com/Webcast/Page/2965/48792You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.About Medicure Inc.Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. (\"Marley Drug\"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected]. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visi...

More updates from Medicure Inc.